Goldman Sachs: JD Health (06618.HK) continues to expand market share, maintains "buy" rating.

Zhixin Financial APP learned that Goldman Sachs released a research report stating that the expected revenue growth of JD Health (06618.HK) in the second quarter roughly meets market expectations. Although the performance during the 618 shopping festival was relatively flat, with the support of continuously gaining market share in core categories, it is currently forecasted that second-quarter revenue will grow by 18% year-on-year. Goldman Sachs currently predicts that JD Health's adjusted operating profit margin in the second quarter will be 7.1%, showing continued improvement year-on-year. The bank also expects growth to accelerate in the second half of the year, maintaining a "buy" rating with a target price of HK$65.